Boardroom Alpha
Boardroom Alpha
PATH · Additional Proxy Materials (DEFA14A) · Filed May 22, 2026

Uipath Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
May 22, 2026
Ticker
PATH
Accession
0001734722-26-000033
Boardroom Alpha · Filing insights

UiPath reduces board to seven after Somasegar's death; votes for him won't be counted.

About Uipath Inc
Market cap
$6.4B
1Y TSR
−14.9%
3Y TSR
−14.8%
Board grade
C-
Sector
Technology
CEO
Daniel Dines
Last annual meeting: Jun 25, 2026 · View full Uipath Inc profile →
Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )


Filed by the Registrant ☒
Filed by a Party other than the Registrant

Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to § 240.14a-12
UiPath, Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply)
No fee required.
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


logo1.jpg


UiPath, Inc.
One Vanderbilt Avenue, 60th Floor
New York, New York 10017

ADDITIONAL MATERIALS FOR PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS

To Be Held On June 25, 2026

May 22, 2026

Notice to our Stockholders:

It is with deep regret that we inform you of the passing of Sivaramakichenane Somasegar on May 19, 2026. Mr. Somasegar had been a director of UiPath, Inc. (“UiPath”) since September 2024 and was a nominee standing for election as a director at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of UiPath to be held on Thursday, June 25, 2026 at 11:00 a.m., Eastern Time.

As a result of Mr. Somasegar’s death, he will no longer stand for election at the Annual Meeting. The Board of Directors of UiPath (the “Board”) has taken action to reduce the size of the Board to eliminate the vacancy, and only the remaining seven nominees named in our Proxy Statement, as filed with the Securities and Exchange Commission on May 12, 2026 (the “Proxy Statement”), will stand for election at the Annual Meeting. The Board has also appointed June Yang to serve on the Nominating and Corporate Governance Committee of the Board.

Any votes cast for Mr. Somasegar will not be counted. If you have already voted your shares by proxy, no further action is needed, and your shares will be voted as specified in your prior vote with respect to the election of the remaining seven nominees, unless you choose to revoke your proxy. If you have not already voted your shares, you may do so by one of the methods described in the Proxy Statement, and your vote with respect to nominees for election as directors will be counted accordingly (other than votes with respect to Mr. Somasegar, which will not be counted).

By Order of the Board of Directors

/s/ Brad Brubaker
Brad Brubaker
Chief Legal Officer and Secretary
New York, New York
May 22, 2026



From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Uipath Inc (PATH)

Reference

Frequently asked questions

When did Uipath Inc file this DEFA14A?
Uipath Inc (PATH) filed this Additional Proxy Materials (DEFA14A) with the SEC on May 22, 2026. The accession number assigned by EDGAR is 0001734722-26-000033.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
UiPath reduces board to seven after Somasegar's death; votes for him won't be counted. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Uipath Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Uipath Inc has filed under CIK 1734722, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer